

MEDIA RELEASE

PHARMANIAGA DELIVERS STRONG FINANCIAL PERFORMANCE, SUPPORTS GOVERNMENT TO SERVE RAKYAT ACROSS VARIOUS HEALTHCARE SECTORS

SHAH ALAM, 1 DECEMBER 2021 – Delivering commendable third quarter financial results, Pharmaniaga Berhad (Pharmaniaga) is well-positioned to continuously support the Government to serve the *rakyat* across various healthcare sectors against COVID-19 and future pandemic, as well as supporting the nation's recovery.

During the quarter, the Group delivered positive returns and growth momentum with Profit After Taxation and Zakat (PAT) of RM50 million and Profit Before Taxation and Zakat (PBT) of RM98 million on the back of a revenue of RM2.1 billion. Within the nine-month period, the Group has achieved PAT of RM87 million and PBT RM152 million while revenue stood at RM4.1 billion.

Speaking to the media after its Q3 Fund Analyst Briefing today, Pharmaniaga Group Managing Director Datuk Zulkarnain Md Eusope said various efforts have been put in place for the Group's next key focuses which are insulin manufacturing, continuous COVID-19 vaccine fill and finish manufacturing, as well as Hepatitis-C treatment.

"Our focus goes beyond the COVID-19 vaccine in the coming quarters. We are in the midst of setting up an insulin manufacturing plant to meet the needs to treat non-communicable diseases (NCDs).

"This plan will complement the Group's strong market presence in the cardiovascular and basic diabetic range. The manufacturing facility will be located at our EU certified high-tech plant, Pharmaniaga LifeScience Sdn Bhd (PLS) and will produce pre-filled insulin cartridges in the form of self-administered 'Pens', and expected to be ready in 2025," he said.

Datuk Zulkarnain said with the proven capabilities and facilities, the Group has recently collaborated with Government's Malaysia Healthcare Travel Council (MHTC) to explore two programmes, namely 'Malaysia as Hepatitis-C Treatment Hub of Asia' and 'COVID-19 and other Vaccination Programmes for Healthcare Travellers'.

For the said two programmes, Datuk Zulkarnain explains that Pharmaniaga's role is to provide the supply, logistics and distribution of Hepatitis C drugs Ravidasvir, COVID-19 and other vaccines to the participating member hospitals of MHTC, access to Key Opinion Leaders (KOLs), provide support for the platform/system for the vaccination programme as well as marketing and promotion, amongst others.

FOR IMMEDIATE RELEASE

MEDIA RELEASE

"Amidst the continued resurgence of COVID-19 cases, we support the Government's effort to drive the country into a hub for COVID-19 vaccine and other vaccines as well as treatment for diseases that will help to increase confidence in using vaccines amongst the rakyat.

"Our current Sinovac COVID-19 stocks are enough to cover Malaysia's booster dose and vaccination for children as we have embarked into an ongoing private vaccination programme.

"And we will continue with Sinovac COVID-19 vaccine fill and finish manufacturing to meet domestic and international demands since we have the expertise, capabilities and facilities, as well as strong and full support from our technical partners from overseas," said Datuk Zulkarnain, adding that Pharmaniaga's production will continue to cater for the needs of other nations, especially in South East Asia countries and African nations.

Moving forward, Datuk Zulkarnain said the Group is optimistic to remain sustainable in its business growth for the next quarter of the financial ending 2021 and committed to enhance its expertise in R&D activities to continue developing new pharmaceutical products amongst others.

"Our logistics and distribution business with the Ministry of Health (MOH) will continue and currently we are in negotiating with the Government to further extend it. The signs are good for us to remain MOH's logistics and distribution partner beyond 2024," he said.

Datuk Zulkarnain extended his gratitude and appreciation on behalf of the Group to the Prime Minister, YAB Dato' Sri Ismail Sabri Yaakob, Minister of Health YB Khairy Jamaluddin and Minister of Science, Technology and Innovation (MOSTI) YB Dato' Dr Adham Baba for the trust and confidence placed in Pharmaniaga to manufacture and export Sinovac fill and finish COVID-19 vaccine in Malaysia and soon to penetrate world's market.

Pharmaniaga is the leading pharmaceutical Company of Boustead Holdings Berhad group of companies, and together with Lembaga Tabung Angkatan Tentera, are the major shareholders of the Company.

-END-

FOR IMMEDIATE RELEASE

MEDIA RELEASE

About Pharmaniaga Berhad

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of the Company. Listed on the Main Board of Bursa Malaysia, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy.

With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and is empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical arena.

Forward-looking statement

This release may contain certain forward-looking statements with respect to the financial conditions, results of operations and business of the Group and certain plans and objectives of Pharmaniaga Berhad with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Issued for Pharmaniaga Group by Corporate Communications Department, Pharmaniaga Berhad. For media enquiries, please contact Dato' Zuhri Iskandar Kamarzaman, Corporate Services Deputy Director of Pharmaniaga Berhad at 03-3342 999 ext 434 or by email zuhri@pharmaniaga.com.